Francesca Bergamo

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino et al. · The Lancet Oncology · 2016 · 1K citations · Full text

Medicine, Oncology, Pharmacology +14

Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan

Chiara Cremolini, Daniele Rossini, Emanuela Dell’Aquila et al. · JAMA Oncology · 2018 · 420 citations · Full text

Medicine, Oncology, Pharmacology +17

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · The Lancet Oncology · 2022 · 270 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

Andrea Sartore‐Bianchi, Filippo Pietrantonio, Sara Lonardi et al. · Nature Medicine · 2022 · 261 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical pattern and associations of oxaliplatin acute neurotoxicity

Andreas A. Argyriou, Guido Cavaletti, Chiara Briani et al. · Cancer · 2012 · 219 citations

Medicine, Oncology, Pharmacology +17